A detailed history of Exodus Point Capital Management, LP transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 107,174 shares of MRSN stock, worth $197,200. This represents 0.0% of its overall portfolio holdings.

Number of Shares
107,174
Holding current value
$197,200
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.0 - $4.45 $214,348 - $476,924
107,174 New
107,174 $215,000
Q1 2023

May 11, 2023

BUY
$4.0 - $7.02 $112,940 - $198,209
28,235 Added 239.3%
40,034 $165,000
Q4 2022

Feb 13, 2023

SELL
$5.65 - $7.86 $822,707 - $1.14 Million
-145,612 Reduced 92.5%
11,799 $69,000
Q3 2022

Nov 10, 2022

BUY
$4.63 - $8.0 $610,613 - $1.06 Million
131,882 Added 516.6%
157,411 $1.06 Million
Q2 2022

Aug 19, 2022

SELL
$2.84 - $5.0 $714,430 - $1.26 Million
-251,560 Reduced 90.79%
25,529 $118,000
Q1 2022

May 13, 2022

BUY
$3.74 - $6.63 $922,575 - $1.64 Million
246,678 Added 811.15%
277,089 $1.11 Million
Q4 2021

Feb 11, 2022

BUY
$5.48 - $9.86 $166,652 - $299,852
30,411 New
30,411 $189,000
Q3 2021

Nov 15, 2021

SELL
$8.56 - $14.47 $181,018 - $305,997
-21,147 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$13.28 - $18.07 $280,832 - $382,126
21,147 New
21,147 $287,000
Q1 2021

May 17, 2021

SELL
$15.31 - $26.52 $500,698 - $867,310
-32,704 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$16.84 - $27.59 $206,357 - $338,087
-12,254 Reduced 27.26%
32,704 $870,000
Q3 2020

Nov 16, 2020

BUY
$16.2 - $25.7 $728,319 - $1.16 Million
44,958 New
44,958 $837,000
Q2 2019

Aug 14, 2019

SELL
$3.84 - $6.4 $209,272 - $348,787
-54,498 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$3.51 - $7.3 $191,287 - $397,835
54,498 New
54,498 $287,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $179M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.